RESUMO
OBJECTIVE: Neuronal Pentraxin 2 (NPTX2) has recently been widely reported as a novel biomarker for Alzheimer's disease (AD), but its correlation with vascular dementia (VaD) has not been elucidated. This study aimed to explore the correlation between NPTX2 and the cognitive function of VaD patients. METHODS: 112 VaD patients and 76 healthy controls were included in the study. Upon admission, clinical baseline data for all subjects were collected. Serum NPTX2 levels were determined using enzyme-linked immunosorbent assay (ELISA). At the same time, the Montreal cognitive assessment (MoCA) scale was used to measure cognitive function. Multivariate regression analysis was used to determine the relationship between serum NPTX2 level and the cognitive function of VaD patients. RESULTS: Compared with healthy controls, VaD patients had lower serum NPTX2 levels (p < .001). The results of Spearman's correlation analysis showed that serum NPTX2 levels in VaD patients were positively correlated with MoCA scores (r = .347, p = .042). The results of multivariate regression analysis showed that after adjusting for common risk factors, serum NPTX2 levels in VaD patients were still significantly associated with MoCA scores (ß = 0.346, p = .039). CONCLUSIONS: Serum NPTX2 level was independently associated with cognitive function in patients with VaD. Serum NPTX2 level may be a novel predictor for cognitive function in VaD.
